Valneva reveals chikungunya vaccine data
VLA1553 had a high seroresponse rate among participants 28 days after receiving a single administration
Read More
Tag: chikungunya
Important milestone for Valneva’s chikungunya vaccine
VLA1553 is a single-dose, live-attenuated vaccine candidate targeting the highly dangerous chikungunya virus
Read More
Enrolment concluded for Valneva’s chikungunya vaccine
Phase 3 trial of single-shot chikungunya vaccine candidate unfolds among an adolescent cohort
Read More
Valneva shares positive chikungunya vaccine results
99% of participants retained very high neutralising antibody levels 12 months after treatment
Read More
